Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
Autolus Therapeutics (Nasdaq: AUTL) will release its third quarter 2026 financial results before U.S. markets open on November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will release its third quarter 2026 financial results before U.S. markets open on November 10, 2026. The release will include operational highlights. Management will host a conference call and webcast at 8:30am EST / 1:30pm GMT to discuss the results and provide a general business update. An audio webcast and replay will be available in the events section of Autolus’ website.
Key Figures
- Results release date
- November 10, 2026
- Third quarter 2026 financial results; before U.S. market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its third quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, November 10, 2026.
Management will host a conference call and webcast at 8:30am EST / 1:30pm GMT to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
